ORLANDO, Fla., Dec. 7, 2015 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today presented data from its Phase III PROLONG-9FP clinical program evaluating the efficacy and long-term safety ...

• In clinical trials, IDELVION maintained factor IX activity levels above 5 percent over 14 days, resulting in a median annualized spontaneous bleeding rate (AsBR) of 0.00 • IDELVION, CSL Behring's ...

CSL Behring announced today that the first patient has been enrolled in its Phase II/III clinical study evaluating the pharmacokinetics (PK), efficacy, and safety of the company's recombinant fusion ...

Please provide your email address to receive an email when new articles are posted on . A long-acting recombinant fusion protein that links coagulation Factor IX with albumin appeared safe and ...

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/w2srzv/analysis_of_the) has announced the addition of the "Analysis of the ...

MELBOURNE, Australia, July 1, 2019 /PRNewswire/ -- Global biotherapeutics leader CSL Behring announced today that the company will support the presentation of new data from its recombinant coagulation ...

First Clinical Trial Site Initiated in CSL Behring Phase II/III Pivotal Study of Recombinant Fusion Protein Linking Coagulation Factor IX With Recombinant Albumin VIENNA, January 12, 2012, 2012 ...

With "fivefold increase in half-life" and "no safety complications whatsoever," CSL Behring's long-acting fusion protein that links recombinant coagulation factor IX with recombinant albumin (rIX-FP) ...

CSL Behring has announced a multi-year, $450 million two-site global capacity expansion - the latest in a series of recent production expansions to meet the growing need for its lifesaving and ...

CSL Behring's hemophilia B gene therapy, Hemgenix, carries a $3.5 million list price. But the company contends that by reducing economic burdens associated with bleeding and prophylactic infusions, ...